Studies identify blood biomarker that may detect advanced CTE in living patients
Two independent studies published in JAMA have linked elevated levels of the tau protein fragment eMTBR-tau in blood plasma to advanced chronic traumatic encephalopathy confirmed at autopsy. The findings from Boston University/Banner Health and Washington University researchers offer a potential path toward diagnosing the disease, currently only possible postmortem, in living individuals and enabling clinical trials. Researchers caution that the results are preliminary, based on small samples, and require larger validation studies before any clinical use.
Key points
- •Elevated plasma eMTBR-tau linked to high-stage CTE in autopsy-confirmed cases from two JAMA studies.
- •Combining with p-tau217 may help differentiate CTE from Alzheimer's disease.
- •Test not yet available or FDA-approved; larger studies needed for validation.
Why this is uncovered
Covered by The New York Times, Scientific American, and university/specialist outlets, with more limited pickup in broader national broadcast media.
This article was generated automatically from primary sources and has not been reviewed by a human editor. Verify claims before sharing.
Two recent studies published in the Journal of the American Medical Association have identified elevated levels of a specific tau protein fragment in blood as a potential biomarker for advanced chronic traumatic encephalopathy (CTE) in living people. CTE, a neurodegenerative disease linked to repetitive head impacts, has until now been definitively diagnosable only through postmortem brain examination.
In a study led by researchers at Boston University and Banner Health, scientists analyzed blood samples collected during life from 21 former American football players who later donated their brains to the BU CTE Center Brain Bank. Autopsies confirmed CTE in 18 of the participants, including 16 with high-stage disease (McKee stages 3 or 4) and two with low-stage disease; three had no CTE. Five of those with CTE also showed Alzheimer’s disease neuropathology (Boston University).
The team measured endogenously cleaved microtubule-binding region tau (eMTBR-tau) in plasma. Concentrations were significantly higher in those with high-stage CTE than in participants with low-stage or no CTE. Levels were highest among individuals with both CTE and Alzheimer’s pathology. A second marker, plasma p-tau217, which tracks closely with Alzheimer’s changes, was elevated only in cases with Alzheimer’s disease and not in CTE alone. This combination could help detect CTE and differentiate it from Alzheimer’s, according to the researchers (Concussion & CTE Foundation).
Michael Alosco, PhD, corresponding author and co-director of clinical research at the BU CTE Center, described the findings as a potential game changer if validated, noting they could open doors to clinical trials and treatments. The study involved 12 professional, seven college, and two high school players. Blood plasma eMTBR-tau was not elevated in low-stage CTE or no-CTE cases (The New York Times).
A complementary study published days earlier, led by Washington University School of Medicine in St. Louis, examined eMTBR-tau243 using mass spectrometry. Researchers initially noted unexpectedly high levels in a patient without Alzheimer’s but with advanced CTE at autopsy. They then tested blood from 11 people with autopsy-confirmed CTE, finding elevated levels compared with healthy individuals that rose with disease severity. The biomarker was elevated in advanced CTE and other mixed 3-repeat/4-repeat tauopathies but not reliably in early-stage CTE, and levels were lower than in Alzheimer’s disease (WashU Medicine).
Overall, the WashU analysis included samples from 229 participants across biorepositories. Co-senior author Chihiro Sato, PhD, noted that the Alzheimer’s biomarker can apply to other tauopathies including CTE, though it is not a standalone test. In individuals with a history of repeated head injury who test negative for Alzheimer’s, elevated levels might indicate CTE (Scientific American).
Both research teams emphasized that the work remains in the discovery phase. Sample sizes are small, representation of low-stage CTE is limited, and larger autopsy-confirmed and clinical validation studies are required. The blood test is not FDA-approved or available for public or clinical diagnostic use. WashU has licensed related technology to C2N Diagnostics, which developed an FDA-cleared Alzheimer’s blood test, but it has not been validated for CTE.
Researchers hope validated biomarkers could enable monitoring of at-risk groups such as former athletes, boxers, and military veterans, support clinical trials of potential therapies targeting tau, and improve understanding of CTE prevalence. Funding for the studies came from the National Institutes of Health, including the National Institute of Neurological Disorders and Stroke and National Institute on Aging.
Sources
- bu.eduhttps://www.bu.edu/articles/2026/blood-test-detect-cte-in-life/
- concussionandcte.orghttps://concussionandcte.org/news/press-release/new-study-identifies-blood-test-that-may-detect-cte-during-life/
- nytimes.comhttps://www.nytimes.com/2026/11/19/science/cte-blood-test-diagnosis.html
- medicine.washu.eduhttps://medicine.washu.edu/news/progress-toward-a-blood-test-for-disease-caused-by-brain-injury/
- scientificamerican.comhttps://www.scientificamerican.com/article/a-watershed-moment-researchers-unveil-first-of-its-kind-blood-test-for-cte/
- jamanetwork.comhttps://jamanetwork.com/journals/jama/fullarticle/2857054
Want to respond?
The Uncovered has no comment section by design — we don't host or moderate discussions. If you still want to read along or join in, you can do so over Nostr, an open protocol where your replies live on your own key instead of on our server. Install NostrComments for Chrome or Firefox and the discussion appears on top of this page. Works on desktop and on Firefox for Android.
Open source, no tracking, free.
More in Health
Researchers analyzing 212 plant-based products sold in the UK detected at least one mycotoxin in every sample, though concentrations remained below European Union guideline levels. The survey of meat alternatives and dairy substitutes, published in Food Control, highlights widespread natural fungal contaminants in grains, legumes and seeds used in these foods. Scientists note potential concerns about cumulative exposure from frequent consumption while stressing the findings do not indicate immediate unsafety.
20 Nov 2026
The Food and Agriculture Organization has released a regional assessment of mycotoxin contamination in Near East and North Africa food systems, identifying gaps in surveillance, laboratories and regulations. The report proposes five priority actions to strengthen prevention, detection and management. Findings were shared at a Codex side event amid climate-driven risks to staple crops.
23 Oct 2026
A study from Rutgers School of Dental Medicine published in PNAS Nexus shows that bacteria can corrode titanium dental implants, releasing microscopic particles that disrupt macrophages. These particles, coated with bacterial toxins, trap immune cells in inflammation, reduce bacterial clearance, and contribute to peri-implantitis and jawbone loss in 10-20% of patients. The work identifies the TRPC1 calcium channel as a potential drug target.
23 Oct 2026